Los puntos clave no están disponibles para este artículo en este momento.
Pembrolizumab demonstrated robust and durable antitumor activity and encouraging survival outcomes with manageable toxicity in patients with previously treated, advanced MSI-H/dMMR endometrial cancer.
O’Malley et al. (Thu,) studied this question.